img

Global Chronic Granulomatous Disease (CGD) Management Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global Chronic Granulomatous Disease (CGD) Management Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application

Chronic Granulomatous Disease (CGD) Management report published by MRAResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Chronic Granulomatous Disease (CGD) Management market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Demand from Neutrophil Function Tests and Genetic Testing are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Chronic Granulomatous Disease (CGD) Management industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2033.
Globally, Chronic Granulomatous Disease (CGD) Management key companies include Clinigen Group plc, Orchard Therapeutics plc2032, Horizon Therapeutics plc, ViroMed. Co. Ltd, Bellicum Pharmaceuticals, Inc, Pfizer Inc, Hoffmann-La Roche Ltd, Novartis AG and Lonza, etc. Clinigen Group plc, Orchard Therapeutics plc2032, Horizon Therapeutics plc are top 3 players and held % share in total in 2022.
Chronic Granulomatous Disease (CGD) Management can be divided into X-Linked Chronic Granulomatous Disease and Autosomal Recessive Chronic Granulomatous Disease, etc. X-Linked Chronic Granulomatous Disease is the mainstream product in the market, accounting for % share globally in 2022.
Chronic Granulomatous Disease (CGD) Management is widely used in various fields, such as Neutrophil Function Tests, Genetic Testing and Prenatal Testing,, etc. Neutrophil Function Tests provides greatest supports to the Chronic Granulomatous Disease (CGD) Management industry development. In 2022, global % share of Chronic Granulomatous Disease (CGD) Management went into Neutrophil Function Tests filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Chronic Granulomatous Disease (CGD) Management market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report



By Company


Clinigen Group plc
Orchard Therapeutics plc2032
Horizon Therapeutics plc
ViroMed. Co. Ltd
Bellicum Pharmaceuticals, Inc
Pfizer Inc
Hoffmann-La Roche Ltd
Novartis AG
Lonza
GlaxoSmithKline plc
Eli Lilly and Company
Johnson & Johnson Services, Inc
Merck KGaA
Segment by Type
X-Linked Chronic Granulomatous Disease
Autosomal Recessive Chronic Granulomatous Disease

Segment by Application


Neutrophil Function Tests
Genetic Testing
Prenatal Testing
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries

Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia

Latin America
Mexico
Brazil

Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Chronic Granulomatous Disease (CGD) Management market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Chronic Granulomatous Disease (CGD) Management introduction, etc. Chronic Granulomatous Disease (CGD) Management Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRAResearch’s Conclusions of Chronic Granulomatous Disease (CGD) Management market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRAResearch.

Table of Content

1 Market Overview of Chronic Granulomatous Disease (CGD) Management
1.1 Chronic Granulomatous Disease (CGD) Management Market Overview
1.1.1 Chronic Granulomatous Disease (CGD) Management Product Scope
1.1.2 Chronic Granulomatous Disease (CGD) Management Market Status and Outlook
1.2 Global Chronic Granulomatous Disease (CGD) Management Market Size Overview by Region 2018 VS 2022 VS 2033
1.3 Global Chronic Granulomatous Disease (CGD) Management Market Size by Region (2018-2033)
1.4 Global Chronic Granulomatous Disease (CGD) Management Historic Market Size by Region (2018-2023)
1.5 Global Chronic Granulomatous Disease (CGD) Management Market Size Forecast by Region (2024-2033)
1.6 Key Regions, Chronic Granulomatous Disease (CGD) Management Market Size (2018-2033)
1.6.1 North America Chronic Granulomatous Disease (CGD) Management Market Size (2018-2033)
1.6.2 Europe Chronic Granulomatous Disease (CGD) Management Market Size (2018-2033)
1.6.3 Asia-Pacific Chronic Granulomatous Disease (CGD) Management Market Size (2018-2033)
1.6.4 Latin America Chronic Granulomatous Disease (CGD) Management Market Size (2018-2033)
1.6.5 Middle East & Africa Chronic Granulomatous Disease (CGD) Management Market Size (2018-2033)
2 Chronic Granulomatous Disease (CGD) Management Market by Type
2.1 Introduction
2.1.1 X-Linked Chronic Granulomatous Disease
2.1.2 Autosomal Recessive Chronic Granulomatous Disease
2.2 Global Chronic Granulomatous Disease (CGD) Management Market Size by Type: 2018 VS 2022 VS 2033
2.2.1 Global Chronic Granulomatous Disease (CGD) Management Historic Market Size by Type (2018-2023)
2.2.2 Global Chronic Granulomatous Disease (CGD) Management Forecasted Market Size by Type (2024-2033)
2.3 Key Regions Market Size by Type
2.3.1 North America Chronic Granulomatous Disease (CGD) Management Revenue Breakdown by Type (2018-2033)
2.3.2 Europe Chronic Granulomatous Disease (CGD) Management Revenue Breakdown by Type (2018-2033)
2.3.3 Asia-Pacific Chronic Granulomatous Disease (CGD) Management Revenue Breakdown by Type (2018-2033)
2.3.4 Latin America Chronic Granulomatous Disease (CGD) Management Revenue Breakdown by Type (2018-2033)
2.3.5 Middle East and Africa Chronic Granulomatous Disease (CGD) Management Revenue Breakdown by Type (2018-2033)
3 Chronic Granulomatous Disease (CGD) Management Market Overview by Application
3.1 Introduction
3.1.1 Neutrophil Function Tests
3.1.2 Genetic Testing
3.1.3 Prenatal Testing
3.2 Global Chronic Granulomatous Disease (CGD) Management Market Size by Application: 2018 VS 2022 VS 2033
3.2.1 Global Chronic Granulomatous Disease (CGD) Management Historic Market Size by Application (2018-2023)
3.2.2 Global Chronic Granulomatous Disease (CGD) Management Forecasted Market Size by Application (2024-2033)
3.3 Key Regions Market Size by Application
3.3.1 North America Chronic Granulomatous Disease (CGD) Management Revenue Breakdown by Application (2018-2033)
3.3.2 Europe Chronic Granulomatous Disease (CGD) Management Revenue Breakdown by Application (2018-2033)
3.3.3 Asia-Pacific Chronic Granulomatous Disease (CGD) Management Revenue Breakdown by Application (2018-2033)
3.3.4 Latin America Chronic Granulomatous Disease (CGD) Management Revenue Breakdown by Application (2018-2033)
3.3.5 Middle East and Africa Chronic Granulomatous Disease (CGD) Management Revenue Breakdown by Application (2018-2033)
4 Chronic Granulomatous Disease (CGD) Management Competition Analysis by Players
4.1 Global Chronic Granulomatous Disease (CGD) Management Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Chronic Granulomatous Disease (CGD) Management as of 2022)
4.3 Date of Key Players Enter into Chronic Granulomatous Disease (CGD) Management Market
4.4 Global Top Players Chronic Granulomatous Disease (CGD) Management Headquarters and Area Served
4.5 Key Players Chronic Granulomatous Disease (CGD) Management Product Solution and Service
4.6 Competitive Status
4.6.1 Chronic Granulomatous Disease (CGD) Management Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Clinigen Group plc
5.1.1 Clinigen Group plc Profile
5.1.2 Clinigen Group plc Main Business
5.1.3 Clinigen Group plc Chronic Granulomatous Disease (CGD) Management Products, Services and Solutions
5.1.4 Clinigen Group plc Chronic Granulomatous Disease (CGD) Management Revenue (US$ Million) & (2018-2023)
5.1.5 Clinigen Group plc Recent Developments
5.2 Orchard Therapeutics plc2032
5.2.1 Orchard Therapeutics plc2032 Profile
5.2.2 Orchard Therapeutics plc2032 Main Business
5.2.3 Orchard Therapeutics plc2032 Chronic Granulomatous Disease (CGD) Management Products, Services and Solutions
5.2.4 Orchard Therapeutics plc2032 Chronic Granulomatous Disease (CGD) Management Revenue (US$ Million) & (2018-2023)
5.2.5 Orchard Therapeutics plc2032 Recent Developments
5.3 Horizon Therapeutics plc
5.3.1 Horizon Therapeutics plc Profile
5.3.2 Horizon Therapeutics plc Main Business
5.3.3 Horizon Therapeutics plc Chronic Granulomatous Disease (CGD) Management Products, Services and Solutions
5.3.4 Horizon Therapeutics plc Chronic Granulomatous Disease (CGD) Management Revenue (US$ Million) & (2018-2023)
5.3.5 ViroMed. Co. Ltd Recent Developments
5.4 ViroMed. Co. Ltd
5.4.1 ViroMed. Co. Ltd Profile
5.4.2 ViroMed. Co. Ltd Main Business
5.4.3 ViroMed. Co. Ltd Chronic Granulomatous Disease (CGD) Management Products, Services and Solutions
5.4.4 ViroMed. Co. Ltd Chronic Granulomatous Disease (CGD) Management Revenue (US$ Million) & (2018-2023)
5.4.5 ViroMed. Co. Ltd Recent Developments
5.5 Bellicum Pharmaceuticals, Inc
5.5.1 Bellicum Pharmaceuticals, Inc Profile
5.5.2 Bellicum Pharmaceuticals, Inc Main Business
5.5.3 Bellicum Pharmaceuticals, Inc Chronic Granulomatous Disease (CGD) Management Products, Services and Solutions
5.5.4 Bellicum Pharmaceuticals, Inc Chronic Granulomatous Disease (CGD) Management Revenue (US$ Million) & (2018-2023)
5.5.5 Bellicum Pharmaceuticals, Inc Recent Developments
5.6 Pfizer Inc
5.6.1 Pfizer Inc Profile
5.6.2 Pfizer Inc Main Business
5.6.3 Pfizer Inc Chronic Granulomatous Disease (CGD) Management Products, Services and Solutions
5.6.4 Pfizer Inc Chronic Granulomatous Disease (CGD) Management Revenue (US$ Million) & (2018-2023)
5.6.5 Pfizer Inc Recent Developments
5.7 Hoffmann-La Roche Ltd
5.7.1 Hoffmann-La Roche Ltd Profile
5.7.2 Hoffmann-La Roche Ltd Main Business
5.7.3 Hoffmann-La Roche Ltd Chronic Granulomatous Disease (CGD) Management Products, Services and Solutions
5.7.4 Hoffmann-La Roche Ltd Chronic Granulomatous Disease (CGD) Management Revenue (US$ Million) & (2018-2023)
5.7.5 Hoffmann-La Roche Ltd Recent Developments
5.8 Novartis AG
5.8.1 Novartis AG Profile
5.8.2 Novartis AG Main Business
5.8.3 Novartis AG Chronic Granulomatous Disease (CGD) Management Products, Services and Solutions
5.8.4 Novartis AG Chronic Granulomatous Disease (CGD) Management Revenue (US$ Million) & (2018-2023)
5.8.5 Novartis AG Recent Developments
5.9 Lonza
5.9.1 Lonza Profile
5.9.2 Lonza Main Business
5.9.3 Lonza Chronic Granulomatous Disease (CGD) Management Products, Services and Solutions
5.9.4 Lonza Chronic Granulomatous Disease (CGD) Management Revenue (US$ Million) & (2018-2023)
5.9.5 Lonza Recent Developments
5.10 GlaxoSmithKline plc
5.10.1 GlaxoSmithKline plc Profile
5.10.2 GlaxoSmithKline plc Main Business
5.10.3 GlaxoSmithKline plc Chronic Granulomatous Disease (CGD) Management Products, Services and Solutions
5.10.4 GlaxoSmithKline plc Chronic Granulomatous Disease (CGD) Management Revenue (US$ Million) & (2018-2023)
5.10.5 GlaxoSmithKline plc Recent Developments
5.11 Eli Lilly and Company
5.11.1 Eli Lilly and Company Profile
5.11.2 Eli Lilly and Company Main Business
5.11.3 Eli Lilly and Company Chronic Granulomatous Disease (CGD) Management Products, Services and Solutions
5.11.4 Eli Lilly and Company Chronic Granulomatous Disease (CGD) Management Revenue (US$ Million) & (2018-2023)
5.11.5 Eli Lilly and Company Recent Developments
5.12 Johnson & Johnson Services, Inc
5.12.1 Johnson & Johnson Services, Inc Profile
5.12.2 Johnson & Johnson Services, Inc Main Business
5.12.3 Johnson & Johnson Services, Inc Chronic Granulomatous Disease (CGD) Management Products, Services and Solutions
5.12.4 Johnson & Johnson Services, Inc Chronic Granulomatous Disease (CGD) Management Revenue (US$ Million) & (2018-2023)
5.12.5 Johnson & Johnson Services, Inc Recent Developments
5.13 Merck KGaA
5.13.1 Merck KGaA Profile
5.13.2 Merck KGaA Main Business
5.13.3 Merck KGaA Chronic Granulomatous Disease (CGD) Management Products, Services and Solutions
5.13.4 Merck KGaA Chronic Granulomatous Disease (CGD) Management Revenue (US$ Million) & (2018-2023)
5.13.5 Merck KGaA Recent Developments
6 North America
6.1 North America Chronic Granulomatous Disease (CGD) Management Market Size by Country (2018-2033)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Chronic Granulomatous Disease (CGD) Management Market Size by Country (2018-2033)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Chronic Granulomatous Disease (CGD) Management Market Size by Region (2018-2033)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Chronic Granulomatous Disease (CGD) Management Market Size by Country (2018-2033)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Chronic Granulomatous Disease (CGD) Management Market Size by Country (2018-2033)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Chronic Granulomatous Disease (CGD) Management Market Dynamics
11.1 Chronic Granulomatous Disease (CGD) Management Industry Trends
11.2 Chronic Granulomatous Disease (CGD) Management Market Drivers
11.3 Chronic Granulomatous Disease (CGD) Management Market Challenges
11.4 Chronic Granulomatous Disease (CGD) Management Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List

List of Figure

List of Tables
Table 1. Global Market Chronic Granulomatous Disease (CGD) Management Market Size (US$ Million) Comparison by Region 2018 VS 2022 VS 2033
Table 2. Global Chronic Granulomatous Disease (CGD) Management Market Size by Region (2018-2023) & (US$ Million)
Table 3. Global Chronic Granulomatous Disease (CGD) Management Market Size Share by Region (2018-2023)
Table 4. Global Chronic Granulomatous Disease (CGD) Management Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 5. Global Chronic Granulomatous Disease (CGD) Management Forecasted Market Size Share by Region (2024-2033)
Table 6. Global Chronic Granulomatous Disease (CGD) Management Market Size (US$ Million) by Type: 2018 VS 2022 VS 2033
Table 7. Global Chronic Granulomatous Disease (CGD) Management Market Size by Type (2018-2023) & (US$ Million)
Table 8. Global Chronic Granulomatous Disease (CGD) Management Revenue Market Share by Type (2018-2023)
Table 9. Global Chronic Granulomatous Disease (CGD) Management Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 10. Global Chronic Granulomatous Disease (CGD) Management Revenue Market Share by Type (2024-2033)
Table 11. North America Chronic Granulomatous Disease (CGD) Management Revenue by Type (2018-2023) & (US$ Million)
Table 12. North America Chronic Granulomatous Disease (CGD) Management Revenue by Type (2024-2033) & (US$ Million)
Table 13. Europe Chronic Granulomatous Disease (CGD) Management Revenue by Type (2018-2023) & (US$ Million)
Table 14. Europe Chronic Granulomatous Disease (CGD) Management Revenue by Type (2024-2033) & (US$ Million)
Table 15. Asia-Pacific Chronic Granulomatous Disease (CGD) Management Revenue by Type (2018-2023) & (US$ Million)
Table 16. Asia-Pacific Chronic Granulomatous Disease (CGD) Management Revenue by Type (2024-2033) & (US$ Million)
Table 17. Latin America Chronic Granulomatous Disease (CGD) Management Revenue by Type (2018-2023) & (US$ Million)
Table 18. Latin America Chronic Granulomatous Disease (CGD) Management Revenue by Type (2024-2033) & (US$ Million)
Table 19. Middle East and Africa Chronic Granulomatous Disease (CGD) Management Revenue by Type (2018-2023) & (US$ Million)
Table 20. Middle East and Africa Chronic Granulomatous Disease (CGD) Management Revenue by Type (2024-2033) & (US$ Million)
Table 21. Global Chronic Granulomatous Disease (CGD) Management Market Size (US$ Million) by Application: 2018 VS 2022 VS 2033
Table 22. Global Chronic Granulomatous Disease (CGD) Management Market Size by Application (2018-2023) & (US$ Million)
Table 23. Global Chronic Granulomatous Disease (CGD) Management Revenue Market Share by Application (2018-2023)
Table 24. Global Chronic Granulomatous Disease (CGD) Management Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 25. Global Chronic Granulomatous Disease (CGD) Management Revenue Market Share by Application (2024-2033)
Table 26. North America Chronic Granulomatous Disease (CGD) Management Revenue by Application (2018-2023) & (US$ Million)
Table 27. North America Chronic Granulomatous Disease (CGD) Management Revenue by Application (2024-2033) & (US$ Million)
Table 28. Europe Chronic Granulomatous Disease (CGD) Management Revenue by Application (2018-2023) & (US$ Million)
Table 29. Europe Chronic Granulomatous Disease (CGD) Management Revenue by Application (2024-2033) & (US$ Million)
Table 30. Asia-Pacific Chronic Granulomatous Disease (CGD) Management Revenue by Application (2018-2023) & (US$ Million)
Table 31. Asia-Pacific Chronic Granulomatous Disease (CGD) Management Revenue by Application (2024-2033) & (US$ Million)
Table 32. Latin America Chronic Granulomatous Disease (CGD) Management Revenue by Application (2018-2023) & (US$ Million)
Table 33. Latin America Chronic Granulomatous Disease (CGD) Management Revenue by Application (2024-2033) & (US$ Million)
Table 34. Middle East and Africa Chronic Granulomatous Disease (CGD) Management Revenue by Application (2018-2023) & (US$ Million)
Table 35. Middle East and Africa Chronic Granulomatous Disease (CGD) Management Revenue by Application (2024-2033) & (US$ Million)
Table 36. Global Chronic Granulomatous Disease (CGD) Management Revenue (US$ Million) by Players (2018-2023)
Table 37. Global Chronic Granulomatous Disease (CGD) Management Revenue Market Share by Players (2018-2023)
Table 38. Global Top Players Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Chronic Granulomatous Disease (CGD) Management as of 2022)
Table 39. Date of Key Players Enter into Chronic Granulomatous Disease (CGD) Management Market
Table 40. Global Chronic Granulomatous Disease (CGD) Management Key Players Headquarters and Area Served
Table 41. Chronic Granulomatous Disease (CGD) Management Product Solution and Service
Table 42. Global Chronic Granulomatous Disease (CGD) Management Players Market Concentration Ratio (CR5 and HHI)
Table 43. Mergers & Acquisitions, Expansion Plans
Table 44. Clinigen Group plc Basic Information List
Table 45. Clinigen Group plc Description and Business Overview
Table 46. Clinigen Group plc Chronic Granulomatous Disease (CGD) Management Products, Services and Solutions
Table 47. Revenue (US$ Million) in Chronic Granulomatous Disease (CGD) Management Business of Clinigen Group plc (2018-2023)
Table 48. Clinigen Group plc Recent Developments
Table 49. Orchard Therapeutics plc2032 Basic Information List
Table 50. Orchard Therapeutics plc2032 Description and Business Overview
Table 51. Orchard Therapeutics plc2032 Chronic Granulomatous Disease (CGD) Management Products, Services and Solutions
Table 52. Revenue (US$ Million) in Chronic Granulomatous Disease (CGD) Management Business of Orchard Therapeutics plc2032 (2018-2023)
Table 53. Orchard Therapeutics plc2032 Recent Developments
Table 54. Horizon Therapeutics plc Basic Information List
Table 55. Horizon Therapeutics plc Description and Business Overview
Table 56. Horizon Therapeutics plc Chronic Granulomatous Disease (CGD) Management Products, Services and Solutions
Table 57. Revenue (US$ Million) in Chronic Granulomatous Disease (CGD) Management Business of Horizon Therapeutics plc (2018-2023)
Table 58. Horizon Therapeutics plc Recent Developments
Table 59. ViroMed. Co. Ltd Basic Information List
Table 60. ViroMed. Co. Ltd Description and Business Overview
Table 61. ViroMed. Co. Ltd Chronic Granulomatous Disease (CGD) Management Products, Services and Solutions
Table 62. Revenue (US$ Million) in Chronic Granulomatous Disease (CGD) Management Business of ViroMed. Co. Ltd (2018-2023)
Table 63. ViroMed. Co. Ltd Recent Developments
Table 64. Bellicum Pharmaceuticals, Inc Basic Information List
Table 65. Bellicum Pharmaceuticals, Inc Description and Business Overview
Table 66. Bellicum Pharmaceuticals, Inc Chronic Granulomatous Disease (CGD) Management Products, Services and Solutions
Table 67. Revenue (US$ Million) in Chronic Granulomatous Disease (CGD) Management Business of Bellicum Pharmaceuticals, Inc (2018-2023)
Table 68. Bellicum Pharmaceuticals, Inc Recent Developments
Table 69. Pfizer Inc Basic Information List
Table 70. Pfizer Inc Description and Business Overview
Table 71. Pfizer Inc Chronic Granulomatous Disease (CGD) Management Products, Services and Solutions
Table 72. Revenue (US$ Million) in Chronic Granulomatous Disease (CGD) Management Business of Pfizer Inc (2018-2023)
Table 73. Pfizer Inc Recent Developments
Table 74. Hoffmann-La Roche Ltd Basic Information List
Table 75. Hoffmann-La Roche Ltd Description and Business Overview
Table 76. Hoffmann-La Roche Ltd Chronic Granulomatous Disease (CGD) Management Products, Services and Solutions
Table 77. Revenue (US$ Million) in Chronic Granulomatous Disease (CGD) Management Business of Hoffmann-La Roche Ltd (2018-2023)
Table 78. Hoffmann-La Roche Ltd Recent Developments
Table 79. Novartis AG Basic Information List
Table 80. Novartis AG Description and Business Overview
Table 81. Novartis AG Chronic Granulomatous Disease (CGD) Management Products, Services and Solutions
Table 82. Revenue (US$ Million) in Chronic Granulomatous Disease (CGD) Management Business of Novartis AG (2018-2023)
Table 83. Novartis AG Recent Developments
Table 84. Lonza Basic Information List
Table 85. Lonza Description and Business Overview
Table 86. Lonza Chronic Granulomatous Disease (CGD) Management Products, Services and Solutions
Table 87. Revenue (US$ Million) in Chronic Granulomatous Disease (CGD) Management Business of Lonza (2018-2023)
Table 88. Lonza Recent Developments
Table 89. GlaxoSmithKline plc Basic Information List
Table 90. GlaxoSmithKline plc Description and Business Overview
Table 91. GlaxoSmithKline plc Chronic Granulomatous Disease (CGD) Management Products, Services and Solutions
Table 92. Revenue (US$ Million) in Chronic Granulomatous Disease (CGD) Management Business of GlaxoSmithKline plc (2018-2023)
Table 93. GlaxoSmithKline plc Recent Developments
Table 94. Eli Lilly and Company Basic Information List
Table 95. Eli Lilly and Company Description and Business Overview
Table 96. Eli Lilly and Company Chronic Granulomatous Disease (CGD) Management Products, Services and Solutions
Table 97. Revenue (US$ Million) in Chronic Granulomatous Disease (CGD) Management Business of Eli Lilly and Company (2018-2023)
Table 98. Eli Lilly and Company Recent Developments
Table 99. Johnson & Johnson Services, Inc Basic Information List
Table 100. Johnson & Johnson Services, Inc Description and Business Overview
Table 101. Johnson & Johnson Services, Inc Chronic Granulomatous Disease (CGD) Management Products, Services and Solutions
Table 102. Revenue (US$ Million) in Chronic Granulomatous Disease (CGD) Management Business of Johnson & Johnson Services, Inc (2018-2023)
Table 103. Johnson & Johnson Services, Inc Recent Developments
Table 104. Merck KGaA Basic Information List
Table 105. Merck KGaA Description and Business Overview
Table 106. Merck KGaA Chronic Granulomatous Disease (CGD) Management Products, Services and Solutions
Table 107. Revenue (US$ Million) in Chronic Granulomatous Disease (CGD) Management Business of Merck KGaA (2018-2023)
Table 108. Merck KGaA Recent Developments
Table 109. North America Chronic Granulomatous Disease (CGD) Management Market Size by Country (2018-2023) & (US$ Million)
Table 110. North America Chronic Granulomatous Disease (CGD) Management Market Size by Country (2024-2033) & (US$ Million)
Table 111. Europe Chronic Granulomatous Disease (CGD) Management Market Size by Country (2018-2023) & (US$ Million)
Table 112. Europe Chronic Granulomatous Disease (CGD) Management Market Size by Country (2024-2033) & (US$ Million)
Table 113. Asia-Pacific Chronic Granulomatous Disease (CGD) Management Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 114. Asia-Pacific Chronic Granulomatous Disease (CGD) Management Market Size by Region (2018-2023) & (US$ Million)
Table 115. Asia-Pacific Chronic Granulomatous Disease (CGD) Management Market Size by Region (2024-2033) & (US$ Million)
Table 116. Asia-Pacific Chronic Granulomatous Disease (CGD) Management Market Share by Region (2018-2023)
Table 117. Asia-Pacific Chronic Granulomatous Disease (CGD) Management Market Share by Region (2024-2033)
Table 118. Latin America Chronic Granulomatous Disease (CGD) Management Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 119. Latin America Chronic Granulomatous Disease (CGD) Management Market Size by Country (2018-2023) & (US$ Million)
Table 120. Latin America Chronic Granulomatous Disease (CGD) Management Market Size by Country (2024-2033) & (US$ Million)
Table 121. Middle East & Africa Chronic Granulomatous Disease (CGD) Management Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 122. Middle East & Africa Chronic Granulomatous Disease (CGD) Management Market Size by Country (2018-2023) & (US$ Million)
Table 123. Middle East & Africa Chronic Granulomatous Disease (CGD) Management Market Size by Country (2024-2033) & (US$ Million)
Table 124. Chronic Granulomatous Disease (CGD) Management Market Trends
Table 125. Chronic Granulomatous Disease (CGD) Management Market Drivers
Table 126. Chronic Granulomatous Disease (CGD) Management Market Challenges
Table 127. Chronic Granulomatous Disease (CGD) Management Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Chronic Granulomatous Disease (CGD) Management Market Size Year-over-Year 2018-2033 & (US$ Million)
Figure 2. Global Chronic Granulomatous Disease (CGD) Management Market Size (US$ Million), 2018 VS 2022 VS 2033
Figure 3. Global Chronic Granulomatous Disease (CGD) Management Market Share by Regions: 2022 VS 2033
Figure 4. Global Chronic Granulomatous Disease (CGD) Management Forecasted Market Size Share by Region (2024-2033)
Figure 5. North America Chronic Granulomatous Disease (CGD) Management Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 6. Europe Chronic Granulomatous Disease (CGD) Management Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 7. Asia-Pacific Chronic Granulomatous Disease (CGD) Management Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 8. Latin America Chronic Granulomatous Disease (CGD) Management Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 9. Middle East & Africa Chronic Granulomatous Disease (CGD) Management Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 10. Product Picture of X-Linked Chronic Granulomatous Disease
Figure 11. Global X-Linked Chronic Granulomatous Disease Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 12. Product Picture of Autosomal Recessive Chronic Granulomatous Disease
Figure 13. Global Autosomal Recessive Chronic Granulomatous Disease Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 14. Global Chronic Granulomatous Disease (CGD) Management Market Size Share by Type: 2022 & 2033
Figure 15. North America Chronic Granulomatous Disease (CGD) Management Revenue Market Share by Type (2018-2033)
Figure 16. Europe Chronic Granulomatous Disease (CGD) Management Revenue Market Share by Type (2018-2033)
Figure 17. Asia-Pacific Chronic Granulomatous Disease (CGD) Management Revenue Market Share by Type (2018-2033)
Figure 18. Latin America Chronic Granulomatous Disease (CGD) Management Revenue Market Share by Type (2018-2033)
Figure 19. Middle East and Africa Chronic Granulomatous Disease (CGD) Management Revenue Market Share by Type (2018-2033)
Figure 20. Neutrophil Function Tests Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 21. Genetic Testing Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 22. Prenatal Testing Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 23. Global Chronic Granulomatous Disease (CGD) Management Market Size Share by Application: 2022 & 2033
Figure 24. North America Chronic Granulomatous Disease (CGD) Management Revenue Market Share by Application (2018-2033)
Figure 25. Europe Chronic Granulomatous Disease (CGD) Management Revenue Market Share by Application (2018-2033)
Figure 26. Asia-Pacific Chronic Granulomatous Disease (CGD) Management Revenue Market Share by Application (2018-2033)
Figure 27. Latin America Chronic Granulomatous Disease (CGD) Management Revenue Market Share by Application (2018-2033)
Figure 28. Middle East and Africa Chronic Granulomatous Disease (CGD) Management Revenue Market Share by Application (2018-2033)
Figure 29. Chronic Granulomatous Disease (CGD) Management Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 30. Global Top 5 and Top 10 Players Chronic Granulomatous Disease (CGD) Management Market Share in 2022
Figure 31. North America Chronic Granulomatous Disease (CGD) Management Market Share by Country (2018-2033)
Figure 32. United States Chronic Granulomatous Disease (CGD) Management Market Size (2018-2033) & (US$ Million)
Figure 33. Canada Chronic Granulomatous Disease (CGD) Management Market Size (2018-2033) & (US$ Million)
Figure 34. Germany Chronic Granulomatous Disease (CGD) Management Market Size (2018-2033) & (US$ Million)
Figure 35. France Chronic Granulomatous Disease (CGD) Management Market Size (2018-2033) & (US$ Million)
Figure 36. U.K. Chronic Granulomatous Disease (CGD) Management Market Size (2018-2033) & (US$ Million)
Figure 37. Italy Chronic Granulomatous Disease (CGD) Management Market Size (2018-2033) & (US$ Million)
Figure 38. Russia Chronic Granulomatous Disease (CGD) Management Market Size (2018-2033) & (US$ Million)
Figure 39. Nordic Countries Chronic Granulomatous Disease (CGD) Management Market Size (2018-2033) & (US$ Million)
Figure 40. Asia-Pacific Chronic Granulomatous Disease (CGD) Management Market Share by Region (2018-2033)
Figure 41. China Chronic Granulomatous Disease (CGD) Management Market Size (2018-2033) & (US$ Million)
Figure 42. Japan Chronic Granulomatous Disease (CGD) Management Market Size (2018-2033) & (US$ Million)
Figure 43. South Korea Chronic Granulomatous Disease (CGD) Management Market Size (2018-2033) & (US$ Million)
Figure 44. Southeast Asia Chronic Granulomatous Disease (CGD) Management Market Size (2018-2033) & (US$ Million)
Figure 45. India Chronic Granulomatous Disease (CGD) Management Market Size (2018-2033) & (US$ Million)
Figure 46. Australia Chronic Granulomatous Disease (CGD) Management Market Size (2018-2033) & (US$ Million)
Figure 47. Latin America Chronic Granulomatous Disease (CGD) Management Market Share by Country (2018-2033)
Figure 48. Mexico Chronic Granulomatous Disease (CGD) Management Market Size (2018-2033) & (US$ Million)
Figure 49. Brazil Chronic Granulomatous Disease (CGD) Management Market Size (2018-2033) & (US$ Million)
Figure 50. Middle East & Africa Chronic Granulomatous Disease (CGD) Management Market Share by Country (2018-2033)
Figure 51. Turkey Chronic Granulomatous Disease (CGD) Management Market Size (2018-2033) & (US$ Million)
Figure 52. Saudi Arabia Chronic Granulomatous Disease (CGD) Management Market Size (2018-2033) & (US$ Million)
Figure 53. UAE Chronic Granulomatous Disease (CGD) Management Market Size (2018-2033) & (US$ Million)
Figure 54. Bottom-up and Top-down Approaches for This Report

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries